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Background: Fluralaner is a novel systemic insecticide and acaricide. The purpose of these studies was to
investigate the pharmacokinetic properties of fluralaner in Beagle dogs following single oral or intravenous
(i.v.) administration.
Methods: Following the oral administration of 12.5, 25 or 50 mg fluralaner/kg body weight (BW), formulated as
chewable tablets or i.v. administration of 12.5 mg fluralaner/kg BW, formulated as i.v. solution to 24 Beagles, plasma
samples were collected until 112 days after treatment. Plasma concentrations of fluralaner were measured using
HPLC-MS/MS. Pharmacokinetic parameters were calculated by non-compartmental methods.
Results: After oral administration, maximum plasma concentrations (Cmax) were reached within 1 day on average.
Fluralaner was quantifiable in plasma for up to 112 days after single oral and i.v. treatment. The apparent half-life
of fluralaner was 12–15 days and the mean residence time was 15–20 days. The apparent volume of distribution of
fluralaner was 3.1 L/kg, and clearance was 0.14 L/kg/day.
Conclusions: Fluralaner is readily absorbed after single-dose oral administration, and has a long elimination half-life,
long mean residence time, relatively high apparent volume of distribution, and low clearance. These pharmacokinetic
characteristics help to explain the prolonged activity of fluralaner against fleas and ticks on dogs after a single oral dose.
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Fluralaner is a novel systemic insecticide and acaricide for-
mulated as a chewable oral tablet that can be administered
to dogs at 12 week intervals for effective persistent killing
of a number of flea and tick species of dogs [1,2].
Fluralaner belongs to a new class of chemicals with an
isoxazoline structure as an essential feature [2,3]. It has a
molecular weight of 556.29, a log Pow (octanol/water parti-
tion co-efficient) of 5.35 and is highly bound to plasma
proteins.
Fluralaner is a potent inhibitor of ligand gated chloride
channels (γ-aminobutyric acid (GABA)- and L-glutamate-
gated chloride channels) in neurons with significant selec-
tivity for arthropod neurons over mammalian neurons
[2,3]. In vivo investigations have shown that after a single
oral administration to dogs, fluralaner provides persistent* Correspondence: susanne.kilp@msd.de
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unless otherwise stated.flea and tick killing activity for 12 weeks [1]. Fluralaner is
an innovative, highly effective, and long-lasting ectopara-
site treatment for dogs.Methods
Chewable tablets containing 13.64% (w/w) fluralaner
were formulated for oral administration to dogs. Test
material for i.v. administration was formulated as solu-
tion with 2.5 mg fluralaner /mL in a Polyethylene glycol
(PEG) 200 (90% v/v) vehicle containing 10% v/v water
for injection.
Healthy male and female Beagle dogs were kept indoors
in pens with sealed floors and individually housed until 5
or 6 weeks after fluralaner administration (oral or i.v.) to
avoid potential cross contamination between animals.
Thereafter, dogs were housed in groups of 3 of the same
treatment group and sex. Room environment was moni-
tored continuously, with a temperature of 15-21°C, rela-
tive humidity of 40-70%, 10–20 air changes per hour and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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fed once daily in the morning with a standard dog diet
and had ad libitum access to water. On the day of oral
fluralaner administration, the dogs received one-half of
their daily food ration shortly before treatment and the
remainder immediately after treatment, because adminis-
tration of chewable tablets containing fluralaner with food
increases its bioavailability [4].
To determine the rate and extent of systemic exposure
after oral administration and oral dose proportionality, a
parallel-group study was conducted with 3 treatment
groups. Dogs received either 12.5, 25, or 50 mg (target
dose) fluralaner/kg BW orally, with the mid dose (25 mg/kg
BW) based on the minimum recommended treatment
dose [1]. Additional pharmacokinetic parameters such as
total body clearance and volume of distribution were de-
termined in a separate study involving 6 Beagles adminis-
tered 12.5 mg fluralaner/kg BW by slow i.v. infusion. All
dose rates in the following sections are expressed in mg
fluralaner per kg BW.
In both studies, dogs were randomized to treatment
groups (3 dogs per sex per group), within sex, and blocked
by body weight to ensure a balanced distribution. Both
studies were compliant with the principles of Good
Laboratory Practice [5]. The animal work was conducted
in compliance with respective national legislation and
approved by Animal Experimentation Ethics Committee
at Harlan Laboratories S.A.
Individual oral doses were determined on the basis of
individual body weights and the nominal content of flur-
alaner in the tablets. Dogs received whole tablets using
either individual 112.5 mg, 250 mg or 500 mg fluralaner
tablets, or a combination of tablets to achieve a dose
close to the calculated target dose. Oral dosing was facil-
itated by placing the calculated target dose on the back
of the dog’s tongue. Intravenous injection dose volumes
were determined on the basis of individual body weights
and were administered as a constant rate infusion over
5 minutes using an automatic injection system (KDS
Model 200, KD Scientific Inc., Holliston, USA). The
injection rate per hour was approximately 12 times the
respective dose volume to ensure complete administra-
tion within 5 minutes.
Blood samples were collected from the jugular vein
into sodium-citrate tubes before and at 2, 4, and 8 hours
and 1, 2, 3, 4, 7, 14, 21, 28, 35, 42, 49, 56, 63, 70, 77, 84,
91, 98, 105, and 112 days after oral dosing and 15 min,
2, 4 and 8 hours, and 1, 2, 3, 4, 7, 14, 21, 28, 35, 49, 63,
77, 91, and 112 days after i.v. dosing. Plasma was harves-
ted by centrifugation and stored frozen in sterile plastic
vials until analysis. The dogs were closely observed for
1 hour after dosing and once daily thereafter.
Plasma samples were extracted by protein precipitation
with acetonitrile and diluted with 0.1% formic acid. Theresultant solution was analyzed quantitatively using
automated solid phase extraction coupled to liquid
chromatography with mass spectrometric detection (online
SPE-HPLC-MS/MS). The linear range of the method for
determination of fluralaner was 10.0 to 2500 ng/mL, with a
lower limit of quantification (LLOQ) of 10.0 ng/mL. Phar-
macokinetic parameters for fluralaner were calculated
using non-compartmental methods with the validated soft-
ware WinNonlin® Professional Version 5.3 (Pharsight Cor-
poration, California, USA). The peak plasma concentration
(Cmax) and time to peak concentration (tmax) were obser-
ved values. The elimination half-life (t1/2) was calculated by
linear regression using the slope of the terminal segment of
the semilogarithmic plasma concentration versus time
curve. The area under the concentration versus time curve
(AUC) from time 0 to the last measurable concentration
(AUC(0→t)) was calculated using the linear trapezoidal rule.
The AUC from time 0 extrapolated to infinity (AUC(0→∞))
was determined as AUC(0→ t) + Ct/λz, where Ct is the
plasma concentration at time t and λz is the first order rate
constant associated with the terminal (log-linear) portion
of the curve. The apparent volume of distribution (Vz) after
i.v. administration, based on the terminal phase was
calculated as Dose/λz × AUC. Total body clearance (Cl)
after i.v. administration was calculated as Dose/AUC.
Bioavailability (F%) via the oral route was calculated using
mean AUC(0→∞) as (AUC(0→∞) oral/AUC(0→∞) iv) × (Dose iv/
Dose oral) × 100. Mean residence time (MRT) extrapolated
to infinity was calculated as the ratio of AUMC/AUC;
where AUMC is the area under the first moment curve.
Dose proportionality was tested for exposure parameters
Cmax and AUC(0→t). For this purpose dose-normalized
(nominal dose) values were analyzed using an appropriate
analysis of variance (ANOVA) regression model. The
tests were two-sided at the 0.05 level of significance.
All data are expressed as arithmetic mean ± SD unless
otherwise stated.
Results and discussion
Each of three groups of six dogs (age 1–2 years; weight
7.8-11.4 kg) was administered fluralaner orally at one of
three target doses (12.5, 25, or 50 mg/kg). The doses were
achieved using whole tablets, and therefore each dog
received a dose around the target dose. This was a range
of 12.0–14.6 mg/kg for a target dose of 12.5 mg/kg, 25.0–
28.8 mg/kg for a target dose of 25 mg/kg, and 42.2–
53.2 mg/kg for a target dose of 50 mg/kg.
No dog showed any clinical finding or adverse event
after oral fluralaner administration.
Plasma concentrations of fluralaner reached Cmax
within 1 day after administration on average, and
progressively declined over time, with some lower
secondary peaks, which may indicate redistribution or
recirculation e.g. enterohepatic re-circulation. There
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concentrations. The terminal portion of the plasma
concentration versus time curves followed an almost
parallel course; in the lower two dose groups at the
same concentration with high inter-individual variabil-
ity, and in the high dose group at a higher concentra-
tion with lower inter-individual variability. Fluralaner
could be quantified in plasma (> 10 ng/mL) for up to
112 days after treatment, demonstrating a long sys-
temic persistence (Figure 1).
In the i.v. (12.5 mg/kg) group very slow elimination of
fluralaner was observed after the 5-minute infusion. In
all dogs, plasma concentrations of fluralaner declined as
a function of time, with some secondary peaks, which
may indicate redistribution or recirculation e.g. entero-
hepatic re-circulation. Fluralaner could be quantified in
plasma for up to 112 days post administration, demon-
strating a long systemic persistence after i.v. administra-
tion to dogs (Figure 2).
The non-compartmental pharmacokinetic parameters
calculated from the concentration–time data of flurala-
ner are shown in Table 1.
The mean total plasma clearance of fluralaner was
0.14 L/kg/day and the mean apparent volume of dis-


























Figure 1 Plasma concentrations of fluralaner (Mean ± Standard Devia
LLOQ (10 ng/mL) were set to zero for calculation of means.The mean half-life (15 days) and mean residence time
(20 days) values suggest a slow elimination process
following i.v. infusion. These parameters were similar
to values determined after oral administration at dif-
ferent dose rates, indicating that the elimination kinetic
appears to be independent of dose and administration
route.
As only unbound drugs in the vascular system are
available to clearing organs for elimination, apparent
volume of distribution and clearance are determinants
of the terminal half-life [7-9]. Taking into account the
total body water volume (approximately 0.6 L/kg) of
a dog [6], fluralaner has a relatively high apparent
distribution (Vz = 3.1 L/kg) into tissues following i.v.
infusion, despite its high level of binding to plasma
proteins.
For fluralaner, it is assumed that the main route of
elimination is likely hepatic, because the high plasma
protein binding suggests that elimination via renal fil-
tration is minor; therefore, plasma clearance can be
assumed to be equivalent to hepatic clearance. Con-
sidering a physiological hepatic blood flow in the dog
of approximately 44.5 L/kg/day [6,7] and hepatic
clearance of fluralaner of 0.14 L/kg/day, the hepatic
extraction ratio is estimated to be low (0.3%). The low
clearance, together with the relatively high distribution to56 70 84 98 112
e (days) 
12.5 mg/kg BW oral
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Figure 2 Plasma concentrations of fluralaner (Mean ± Standard Deviation) in dogs following single i.v. administration. Values below
LLOQ (10 ng/mL) were set to zero for calculation of means.
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of fluralaner in the dog.
The bioavailability of the oral formulation is slightly
higher at lower oral doses (34 ± 16%, 26 ± 11%, and 20 ±
8%, for 12.5, 25 and 50 mg/kg, respectively).
However, there was no statistically significant differ-
ences between dose groups in dose-normalized exposure
parameters AUC(0→t) and Cmax (ANOVA, p = 0.165 for
AUC(0→t) and p = 0.206 for Cmax), indicating no evidence
against the null hypothesis of fluralaner dose proportion-
ality over the dose range 12.5 mg/kg to 50 mg/kg.Table 1 Plasma pharmacokinetic parameters of fluralaner in d




Cmax (ng/mL) 2144 ± 860 3948 ± 173
tmax
a (day) 1 (range 0.08–2) 1 (range 1–
AUC(0-d112) (day* ng/mL) 29665 ± 13858 46115 ± 18
AUC(0→∞) (day*ng/mL) 29922 ± 13808 46416 ± 18
t1/2 (day) 13 ± 1 12 ± 3
MRT (day) 19 ± 2 15 ± 4
Cl (L/kg/day) n/a n/a
Vz (L/kg) n/a n/a
aMedian, other values are mean ± standard deviation.
n/a - not applicable.Conclusions
Fluralaner is readily absorbed after single-dose oral admin-
istration, and has a long elimination half-life, long mean
residence time, relatively high apparent volume of distribu-
tion, and low clearance. These pharmacokinetic character-
istics help to explain the prolonged activity of fluralaner
against fleas and ticks on dogs after a single oral dose.
Compliance statement
This study was conducted in Spain after obtaining the
authorization of the relevant regulatory authorities.ogs after either single oral or single i.v. administration




4 5419 ± 2086 7109 ± 908
2) 1 (range 0.17–3) n/a
932 70171 ± 26412 87198 ± 11835
929 70531 ± 26529 87779 ± 12004
14 ± 1 15 ± 2
17 ± 3 20 ± 3
n/a 0.14 ± 0.02
n/a 3.1 ± 0.5
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